Britain is at a crossroads on weight loss medications

And, if so, what will this mean for future health inequalities?

There is no doubt that weight loss medications, such as Wegovy or Mounjaro, represent a major advance in obesity management. They can support clinically meaningful weight loss and, for many, help break the exhausting cycle of repeated weight loss and regain, although it’s important to note that they don’t work for everyone. With obesity among the UK’s leading causes of preventable illness, costing the NHS an estimated £6.5 billion a year, these drugs offer a valuable tool. However, they are not a replacement for the fundamentals of a healthy lifestyle.

These drugs work largely by suppressing appetite, which means that people eat less. In a population where many adults already fall short of recommended fibre, calcium, folate, iodine, iron, vitamin A and B12, reduced food consumption can make it harder to meet nutritional needs without guidance towards nutrient-dense choices. Appetite suppression can also contribute to side effects such as nausea and constipation, which can often be mitigated through a balanced diet.

Without nutritional guidance, users risk losing a significant proportion of muscle alongside body fat. Evidence shows that maintaining muscle mass requires both strength-building exercise and adequate dietary protein, which can be harder to achieve when appetite is suppressed. Failing to preserve muscle can store up problems for later life, increasing the risk of reduced mobility, metabolic issues and chronic health conditions as people age and so avoiding loss of muscle during weight loss is important for future health.

Around 29 million people in England meet the eligibility criteria for treatment under NICE and MHRA guidance. Yet only around 220,000 will be treated through the NHS in the first three years. Meanwhile, growing numbers are accessing weight loss medications privately, sometimes through unregulated routes, without clinical monitoring or nutritional advice. These users may miss out on essential guidance on diet, hydration and lifestyle that is critical for safe and effective treatment and maximising long-term benefits.

Weight loss medication should complement, not replace, guidance on healthy eating and physical activity. With NHS prescribing currently limited to a maximum of two years, people need support to build long-term habits that will last beyond the prescription period.

The wider issue is that Britain still lacks the supportive food environment needed to make healthy choices easier. If we shift prematurely towards a “medication-first” culture without investing equally in reshaping the food environment, nutrition education, behaviour-change support and preventative public measures, we risk deepening existing inequalities rather than reducing them.

Weight loss medications must be part of a broader strategy. Improving diet and increasing opportunities for physical activity must remain central to efforts to improve the nation’s health. If we fail to pair medical innovation with robust public health action, we risk creating a system in which the benefits of these treatments are unevenly distributed, flowing to some while failing to reach those who need them most and where long-term health gains are limited because users do not receive the support to sustain them. Britain now has an opportunity to harness these drugs to improve health, success will depend on ensuring they sit alongside, rather than overshadow, the foundational pillars of good nutrition, physical activity and long-term support.

____________________

Sara Stanner is the Science Director at the British Nutrition Foundation

LBC Opinion provides a platform for diverse opinions on current affairs and matters of public interest.

The views expressed are those of the authors and do not necessarily reflect the official LBC position.

To contact us email views@lbc.co.uk